← Back to patent-cliff list
Pidnarulex
Tier C — Watch / tradePidnarulex
Cylene
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：POLR2, POLR1A
Indications (approved)：Colorectal cancer, Solid tumour, Burkitt淋巴瘤, B-cell lymphoma, Lymphoma, HR阳性乳腺癌, Breast cancer, 三阴性乳腺癌
Regional status
US
Phase II
2025-07-16
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pidnarulex?
Approved indications include: Colorectal cancer, Solid tumour, Burkitt淋巴瘤, B-cell lymphoma, Lymphoma, HR阳性乳腺癌, Breast cancer, 三阴性乳腺癌.
When does the Pidnarulex patent expire?
No public expiry year is available for Pidnarulex yet; this page updates once verified.
How do I get a quote for Pidnarulex intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30